NCT05444374 is a Phase 2 clinical trial of Serplulimab in Cervical Cancer, sponsored by Sichuan Cancer Hospital and Research Institute.

Who is sponsoring NCT05444374?

NCT05444374 is sponsored by Sichuan Cancer Hospital and Research Institute.

What drugs are being tested in NCT05444374?

Interventions in NCT05444374: Serplulimab, Bevacizumab.

What condition does NCT05444374 study?

NCT05444374 studies Cervical Cancer.

Is NCT05444374 still recruiting?

NCT05444374 is currently status unknown. Last updated 5 July 2022.

Last reviewed 2022-07-05 · How we verify

NCT05444374

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer

Status unknown Phase 2 Last updated 5 July 2022

What this trial tests

Phase 2 trial testing Serplulimab in Cervical Cancer in 48 participants. Status unknown.

Timeline

1 October 2022

Primary endpoint
30 September 2024

31 December 2025

Quick facts

Lead sponsor	Sichuan Cancer Hospital and Research Institute
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	48
Start date	1 October 2022
Primary completion	30 September 2024
Estimated completion	31 December 2025
Sites	4 locations across China

Drugs / interventions tested

Serplulimab — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →

Conditions studied

Cervical Cancer — all drugs for Cervical Cancer →

Sponsor

Sichuan Cancer Hospital and Research Institute

Who can join

Adults 18 to 75, female only, with Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single-arm, multicenter, Phase II study to evaluate the efficacy and safety of the treatment of Serplulimab plus Bevacizumab in combination with chemotherapy in 1L treatment of patients with untreated recurrent or metastatic cervical cancer. Approximately 48 eligible subjects are planned to be enrolled across all sites. The dosing regimen is: Serplulimab plus Bevacizumab combined with chemotherapy (cisplatin, paclitaxel). Each cycle is 21 days (every 3 weeks). Subjects will receive Cisplatin plus Paclitaxel up to 4-6 cycles. The maximum duration of treatment with Serplulimab is 2 years (up to 35 cycles). During the study treatment period, the subjects will receive imaging examination and response assessments every 6 weeks (± 7 days) in the first 48 weeks, every 9 weeks (± 7 days) in 48-96 weeks, and then every 12 weeks (± 7 days). After the treatment discontinuation visit, the subjects will enter the safety follow-up period and survival follow-up period.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge.
Li C, Cang W, Gu Y, Chen L, et al · · 2023 · cited 19× · PMID 37559727 · DOI 10.3389/fimmu.2023.1195476
Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study.
An J, Li X, Wang J, Zhu L, et al · · 2023 · cited 13× · PMID 37153587 · DOI 10.3389/fimmu.2023.1142256
Immune checkpoint inhibitors in gynecologic oncology: Current status and perspectives.
Yanaihara N, Tse KY, Lee SJ, Yoo JG, et al · · 2025 · cited 4× · PMID 40908776 · DOI 10.1002/ijgo.70280

Verify or expand the search:

Other trials of Serplulimab

Trials testing the same drug.

NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07446465 — FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectab · Phase 4 · not yet recruiting
NCT07403435 — Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC · Phase 2 · not yet recruiting
NCT07381400 — Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Stu · Phase 2 · not yet recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Other Sichuan Cancer Hospital and Research Institute trials

Trials by the same sponsor.

NCT07269912 — Application of Multimodal MRI in Histological Grading and Prognostic Assessment of Rectal Cancer · not yet recruiting
NCT07082699 — The Efficacy of Antegrade and Retrograde Enemas Management in Low Anterior Resection Syndrome and Improving the Rate of · NA · not yet recruiting
NCT06939764 — Application of the sG8 Scale in Real-World Geriatric Oncology Patients · not yet recruiting
NCT06717854 — Retrograde and Antegrade Enema for Prevention of LARS After LAR: a Randomized Controlled Trial · NA · not yet recruiting
NCT06860685 — Trial of Gum Chewing to Enhance the Restoration of Intestinal Motility in Colorectal Cancer Surgery · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05444374 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sichuan Cancer Hospital and Research Institute
Last refreshed: 5 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05444374.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing